Supernus Pharmaceuticals, Inc. revised earnings guidance for the full year 2023. For the year, the company expected total revenues to be in the range of $590 million to $610 million compared to previous guidance $580 million to $620 million and Operating loss to be in the range of $15 million to $5 million compared to previous guidance $30 million to $10 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.07 USD | +2.59% | +2.28% | +3.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.90% | 1.65B | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023